Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

被引：1
|
作者：
Rizk, Mohamed [1 ]
Rizq, Ola [2 ]
Oshima, Motohiko [1 ]
Nakajima-Takagi, Yaeko [1 ]
Koide, Shuhei [1 ]
Saraya, Atsunori [3 ]
Isshiki, Yusuke [4 ]
Chiba, Tetsuhiro [5 ]
Yamazaki, Satoshi [6 ]
Ma, Anqi [7 ,8 ]
Jin, Jian [7 ,8 ]
Iwama, Atsushi [1 ]
Mimura, Naoya [9 ]
机构：
[1] Univ Tokyo, Inst Med Sci, Div Stem Cell & Mol Med, Ctr Stem Cell Biol & Regenerat Med, Tokyo, Japan
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan
[4] Oami Municipal Hosp, Dept Hematol, Chiba, Japan
[5] Chiba Univ Hosp, Dept Gastroenterol, Chiba, Japan
[6] Univ Tokyo, Inst Med Sci, Div Stem Cell Biol, Ctr Stem Cell Biol & Regenerat Med, Tokyo, Japan
[7] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pharmacol Sci, Mt Sinai Ctr Therapeut Discovery, New York, NY 10029 USA
[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, Mt Sinai Ctr Therapeut Discovery, New York, NY 10029 USA
[9] Chiba Univ Hosp, Dept Transfus Med & Cell Therapy, Chiba, Japan
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122157
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4400
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Mechanism of action of synergistic activity of EZH2 inhibition and IMiDs in preclinical multiple myeloma models
    Drew, Allison E.
    Motwani, Vinny
    Eichinger, Lindsey
    Smith, Jesse
    Raimondi, Alejandra
    CANCER RESEARCH, 2018, 78 (13)
  • [32] EZH1-PRC2 Identifies a Potential Reservoir for Disease Relapse in Quiescent Cancer Cells Refractory to EZH2 Enzymatic Inhibition
    Healy, Evan
    McCole, Rachel
    Monger, Craig
    Nolan, James
    Conway, Eric
    Brien, Gerard
    Wang, Cheng
    Neikes, Hannah K.
    Potjewyd, Frances
    Vermeulen, Michiel
    Mooney, Aoibhinn
    Flavin, Richard
    Vandenberghe, Elisabeth
    James, Lindsey, I
    Bracken, Adrian P.
    BLOOD, 2022, 140 : 3049 - 3050
  • [33] DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2
    Kaarijaervi, Roosa
    Kaljunen, Heidi
    Nappi, Lucia
    Fazli, Ladan
    Kung, Sonia H. Y.
    Hartikainen, Jaana M.
    Paakinaho, Ville
    Capra, Janne
    Rilla, Kirsi
    Malinen, Marjo
    Maekinen, Petri I.
    Ylae-Herttuala, Seppo
    Zoubeidi, Amina
    Wang, Yuzhuo
    Gleave, Martin E.
    Hiltunen, Mikko
    Ketola, Kirsi
    COMMUNICATIONS BIOLOGY, 2024, 7 (01)
  • [34] EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition
    Romero, Pierre
    Richart, Laia
    Aflaki, Setareh
    Petitalot, Ambre
    Burton, Megan
    Michaud, Audrey
    Masliah-Planchon, Julien
    Kuhnowski, Frederique
    Le Cam, Samuel
    Balinas-Gavira, Carlos
    Meaudre, Celine
    Luscan, Armelle
    Hamza, Abderaouf
    Legoix, Patricia
    Vincent-Salomon, Anne
    Wassef, Michel
    Holoch, Daniel
    Margueron, Raphael
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [35] EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation
    Adamik, Juraj
    Jin, Shunqian
    Sun, Quanhong
    Zhang, Peng
    Weiss, Kurt R.
    Anderson, Judith L.
    Silbermann, Rebecca
    Roodman, G. David
    Galson, Deborah L.
    MOLECULAR CANCER RESEARCH, 2017, 15 (04) : 405 - 417
  • [36] Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells
    Liu, Zhaoyun
    Jia, Yue
    Yang, Chun
    Liu, Hui
    Shen, Hongli
    Wang, Hao
    Fu, Rong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (10)
  • [37] EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
    Alzrigat, Mohammad
    Parraga, Alba Atienza
    Agarwal, Prasoon
    Zureigat, Hadil
    Osterborg, Anders
    Nahi, Hareth
    Ma, Anqi
    Jin, Jian
    Nilsson, Kenneth
    Oberg, Fredrik
    Kalushkova, Antonia
    Jernberg-Wiklund, Helena
    ONCOTARGET, 2017, 8 (06) : 10213 - 10224
  • [38] Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
    Stamato, Maria Angelica
    Juli, Giada
    Romeo, Enrica
    Ronchetti, Domenica
    Arbitrio, Mariamena
    Caracciolo, Daniele
    Neri, Antonino
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    Amodio, Nicola
    ONCOTARGET, 2017, 8 (63) : 106527 - 106537
  • [39] Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor
    Honma, Daisuke
    Kanno, Osamu
    Watanabe, Jun
    Kinoshita, Junzo
    Hirasawa, Makoto
    Nosaka, Emi
    Shiroishi, Machiko
    Takizawa, Takeshi
    Yasumatsu, Isao
    Horiuchi, Takao
    Nakao, Akira
    Suzuki, Keisuke
    Yamasaki, Tomonori
    Nakajima, Katsuyoshi
    Hayakawa, Miho
    Yamazaki, Takanori
    Yadav, Ajay Singh
    Adachi, Nobuaki
    CANCER SCIENCE, 2017, 108 (10): : 2069 - 2078
  • [40] EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
    Hernando, Henar
    Gelato, Kathy A.
    Lesche, Ralf
    Beckmann, Georg
    Koehr, Silke
    Otto, Saskia
    Steigemann, Patrick
    Stresemann, Carlo
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (02) : 287 - 298
12345